The rest were excluded as they did not meet our PICO criteria; incorrect population (not low-renin hypertension), intervention (not a randomised controlled trial assessing effect of MRA), comparison (not placebo or active drug) or outcome (change in BP, end-organ dysfunction or adverse effects were not reported). The gene discussed is REN; the disease is Hypertension.